|
Impact of rosiglitazone therapy on the lipid profile, glycemic control, and medication costs among type 2 diabetes patients |
Suh DC, Lee DH, McGuire M, Kim CM |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Suh DC, Lee DH, McGuire M, Kim CM. Impact of rosiglitazone therapy on the lipid profile, glycemic control, and medication costs among type 2 diabetes patients. Current Medical Research and Opinion 2011; 27(8): 1623-33 Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Aged, 80 and over; Cholesterol, LDL /blood; Databases, Factual; Diabetes Mellitus, Type 2 /blood /drug therapy /economics; Female; Hemoglobin A, Glycosylated /analysis /metabolism; Humans; Hypoglycemic Agents /administration & Male; Metformin /administration & Middle Aged; Models, Theoretical; Retrospective Studies; Sulfonylurea Compounds /administration & Thiazolidinediones /administration & dosage /economics; dosage /economics; dosage /economics; dosage /economics AccessionNumber 22012000184 Date bibliographic record published 31/03/2012 |
|
|
|